Skip to main content

Advertisement

SpringerLink
Log in

Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Aggressive fibromatosis (AF) is usually a slowly growing locally invasive tumor, but may exhibit a much more aggressive phenotype. The role of chemotherapy in AF is not well defined, but can be useful in some cases. We examined the response of a case to both imatinib and sunitinib.

Methods

We report a case of an aggressive multicentric extra-abdominal AF that was responsive to sunitinib, but resistant to imatinib.

Results

A 23-year-old woman developed painful multifocal AF of both legs and gluteal muscles that progressed after surgery and treatment with methotrexate/vinblastine and pegylated-liposomal doxorubicin. She received six cycles of ifosfamide/etoposide (IMV), and obtained a good response with elimination of pain. After 5 months, she developed progression and again received six cycles of IMV, with cessation of symptoms. After 13 months, tumors recurred. Although the AF was symptomatic and progressing, she was hesitant to receive chemotherapy and began treatment with sunitinib 50 mg/day for 28 days of a 42-day cycle. At 4 months, she could walk on her heels without pain. After 13 months of sunitinib, therapy was changed to imatinib 400 mg/day; after 7 days she noticed increasing pain in the AF lesions and decreased knee flexibility. Imatinib was continued, but after 2 months of imatinib, she could only walk a few steps due to pain. Sunitinib was reinstituted at 37.5 mg/day and symptoms improved within 1.5 weeks, with a marked reduction of symptoms at 1 month. She was doing well with a normal activity level, 32 months after initially beginning sunitinib.

Conclusions

We conclude that sunitinib may be useful in some cases of AF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

References

  1. Alman BA, Greel DA, Ruby LK, Goldberg MJ, Wolfe HJ (1996) Regulation of proliferation and platelet-derived growth factor expression in palmar fibromatosis (Dupuytren contracture) by mechanical strain. J Orthop Res 14:722–728

    Article  PubMed  CAS  Google Scholar 

  2. Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ (1997) Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 151:329–334

    PubMed  CAS  Google Scholar 

  3. Alman BA, Pajerski ME, Diaz-Cano S, Corboy K, Wolfe HJ (1997) Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder. Diagn Mol Pathol 6:98–101

    Article  PubMed  CAS  Google Scholar 

  4. Bertario L, Russo A, Sala P, Eboli M, Giarola M, D’Amico F, Gismondi V, Varesco L, Pierotti MA, Radice P (2001) Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer 95:102–107

    Article  PubMed  CAS  Google Scholar 

  5. Bhama PK, Chugh R, Baker LH, Doherty GM (2006) Gardner’s syndrome in a 40-year-old woman: successful treatment of locally aggressive desmoid tumors with cytotoxic chemotherapy. World J Surg Oncol 4:96

    Article  PubMed  Google Scholar 

  6. Bus PJ, Verspaget HW, van Krieken JH, de Roos A, Keizer HJ, Bemelman WA, Vasen HF, Lamers CB, Griffioen G (1999) Treatment of mesenteric desmoid tumours with the anti-oestrogenic agent toremifene: case histories and an overview of the literature. Eur J Gastroenterol Hepatol 11:1179–1183

    Article  PubMed  CAS  Google Scholar 

  7. Cheon SS, Cheah AY, Turley S, Nadesan P, Poon R, Clevers H, Alman BA (2002) Beta-catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci USA 99:6973–6978

    Article  PubMed  CAS  Google Scholar 

  8. Couture J, Mitri A, Lagace R, Smits R, Berk T, Bouchard HL, Fodde R, Alman B, Bapat B (2000) A germline mutation at the extreme 3′ end of the APC gene results in a severe desmoid phenotype and is associated with overexpression of beta-catenin in the desmoid tumor. Clin Genet 57:205–212

    Article  PubMed  CAS  Google Scholar 

  9. de Andrade CR, Cotrin P, Graner E, Almeida OP, Sauk JJ, Coletta RD (2001) Transforming growth factor-beta1 autocrine stimulation regulates fibroblast proliferation in hereditary gingival fibromatosis. J Periodontol 72:1726–1733

    Article  PubMed  Google Scholar 

  10. Farmer KC, Hawley PR, Phillips RK (1994) Desmoid disease. In: Phillips RK, Spigelman AD, Thompson JP (eds) Familial adenomatous polyposis and other polyposis syndromes. Edward Arnold, London, pp 128–142

    Google Scholar 

  11. Folli F, Galimberti G, Pastore M, Davalli AM, Bosi E (2006) Paraneoplastic insulin resistance syndrome in advanced aggressive fibromatosis (desmoid tumor) treated by imatinib mesylate. Diabetes Care 29:2178–2180

    Article  PubMed  Google Scholar 

  12. Gebert C, Hardes J, Kersting C, August C, Supper H, Winkelmann W, Buerger H, Gosheger G (2007) Expression of beta-catenin and p53 are prognostic factors in deep aggressive fibromatosis. Histopathology 50:491–497

    Article  PubMed  CAS  Google Scholar 

  13. Gega M, Yanagi H, Yoshikawa R, Noda M, Ikeuchi H, Tsukamoto K, Oshima T, Fujiwara Y, Gondo N, Tamura K, Utsunomiya J, Hashimoto-Tamaoki T, Yamamura T (2006) Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 24:102–105

    Article  PubMed  CAS  Google Scholar 

  14. Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G (2004) High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 100:612–620

    Article  PubMed  CAS  Google Scholar 

  15. Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA (2006) Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 24:1195–1203

    Article  PubMed  CAS  Google Scholar 

  16. Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG (2008) Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 14:2717–2725

    Article  PubMed  CAS  Google Scholar 

  17. Hosalkar HS, Torbert JT, Fox EJ, Delaney TF, Aboulafia AJ, Lackman RD (2008) Musculoskeletal desmoid tumors. J Am Acad Orthop Surg 16:188–198

    PubMed  Google Scholar 

  18. Lazar AJ, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, Warneke CL, Lopez-Terrada D, Pollock RE, Lev D (2008) Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 173:1518–1527

    Article  PubMed  CAS  Google Scholar 

  19. Lev D, Kotilingam D, Wei C, Ballo MT, Zagars GK, Pisters PW, Lazar AA, Patel SR, Benjamin RS, Pollock RE (2007) Optimizing treatment of desmoid tumors. J Clin Oncol 25:1785–1791

    Article  PubMed  Google Scholar 

  20. Lewis JJ, Boland PJ, Leung DH, Woodruff JM, Brennan MF (1999) The enigma of desmoid tumors. Ann Surg 229:866–872 discussion 872–3

    Article  PubMed  CAS  Google Scholar 

  21. Li M, Cordon-Cardo C, Gerald WL, Rosai J (1996) Desmoid fibromatosis is a clonal process. Hum Pathol 27:939–943

    Article  PubMed  CAS  Google Scholar 

  22. Lucas DR, Shroyer KR, McCarthy PJ, Markham NE, Fujita M, Enomoto TE (1997) Desmoid tumor is a clonal cellular proliferation: PCR amplification of HUMARA for analysis of patterns of X-chromosome inactivation. Am J Surg Pathol 21:306–311

    Article  PubMed  CAS  Google Scholar 

  23. Mace J, Sybil Biermann J, Sondak V, McGinn C, Hayes C, Thomas D, Baker L (2002) Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 95:2373–2379

    Article  PubMed  CAS  Google Scholar 

  24. Magro G, Lanteri E, Micali G, Paravizzini G, Travali S, Lanzafame S (1997) Myofibroblasts of palmar fibromatosis co-express transforming growth factor-alpha and epidermal growth factor receptor. J Pathol 181:213–217

    Article  PubMed  CAS  Google Scholar 

  25. Middleton SB, Frayling IM, Phillips RK (2000) Desmoids in familial adenomatous polyposis are monoclonal proliferations. Br J Cancer 82:827–832

    Article  PubMed  CAS  Google Scholar 

  26. Okuno SH, Edmonson JH (2003) Combination chemotherapy for desmoid tumors. Cancer 97:1134–1135

    Article  PubMed  Google Scholar 

  27. Patel SR, Benjamin RS (2006) Desmoid tumors respond to chemotherapy: defying the dogma in oncology. J Clin Oncol 24:11–12

    Article  PubMed  Google Scholar 

  28. Patel SR, Evans HL, Benjamin RS (1993) Combination chemotherapy in adult desmoid tumors. Cancer 72:3244–3247

    Article  PubMed  CAS  Google Scholar 

  29. Rakheja D, Cunningham JC, Mitui M, Patel AS, Tomlinson GE, Weinberg AG (2008) A subset of cranial fasciitis is associated with dysregulation of the Wnt/beta-catenin pathway. Mod Pathol 21(11):1330–1336

    Article  PubMed  CAS  Google Scholar 

  30. Saito T, Oda Y, Kawaguchi K, Tanaka K, Matsuda S, Tamiya S, Iwamoto Y, Tsuneyoshi M (2002) Possible association between higher beta-catenin mRNA expression and mutated beta-catenin in sporadic desmoid tumors: real-time semiquantitative assay by TaqMan polymerase chain reaction. Lab Invest 82:97–103

    PubMed  CAS  Google Scholar 

  31. Seinfeld J, Kleinschmidt-Demasters BK, Tayal S, Lillehei KO (2006) Desmoid-type fibromatoses involving the brachial plexus: treatment options and assessment of c-KIT mutational status. J Neurosurg 104:749–756

    Article  PubMed  CAS  Google Scholar 

  32. Skubitz KM, D’Adamo DR (2007) Sarcoma. Mayo Clin Proc 82:1409–1432

    Article  PubMed  CAS  Google Scholar 

  33. Skubitz KM, Skubitz AP (2004) Characterization of sarcomas by means of gene expression. J Lab Clin Med 144:78–91

    Article  PubMed  CAS  Google Scholar 

  34. Skubitz KM, Skubitz AP (2004) Gene expression in aggressive fibromatosis. J Lab Clin Med 143:89–98

    Article  PubMed  CAS  Google Scholar 

  35. Skubitz KM, Hamdan H, Thompson RC Jr (1993) Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. Cancer 72:2963–2969

    Article  PubMed  CAS  Google Scholar 

  36. Skubitz KM, Pambuccian S, Manivel JC, Skubitz AP (2008) Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med 6:23

    Article  PubMed  Google Scholar 

  37. Smith AJ, Lewis JJ, Merchant NB, Leung DH, Woodruff JM, Brennan MF (2000) Surgical management of intra-abdominal desmoid tumours. Br J Surg 87:608–613

    Article  PubMed  CAS  Google Scholar 

  38. Tejpar S, Nollet F, Li C, Wunder JS, Michils G, dal Cin P, Van Cutsem E, Bapat B, van Roy F, Cassiman JJ, Alman BA (1999) Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 18:6615–6620

    Article  PubMed  CAS  Google Scholar 

  39. Wcislo G, Szarlej-Wcislo K, Szczylik C (2007) Control of aggressive fibromatosis by treatment with imatinib mesylate: a case report and review of the literature. J Cancer Res Clin Oncol 133(8):533–538

    Article  PubMed  Google Scholar 

  40. Weiss AJ, Horowitz S, Lackman RD (1999) Therapy of desmoid tumors and fibromatosis using vinorelbine. Am J Clin Oncol 22:193–195

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

KMS has received research funding from Novartis and Pfizer (makers of imatinib and sunitinib), is on the speakers bureau for Novarits (imatinib in CML and GIST) and Pfizer (sunitinib for renal cancer and GIST), and has been a consultant for Novartis (imatinib in CML).

Author information

Authors and Affiliations

  1. Department of Medicine, The University of Minnesota Medical School, The Masonic Cancer Center, Box 286 University Hospital, Minneapolis, MN, 55455, USA

    Keith M. Skubitz

  2. Department of Laboratory Medicine and Pathology, The University of Minnesota Medical School, The Masonic Cancer Center, Minneapolis, MN, 55455, USA

    J. Carlos Manivel

  3. Department of Orthopedic Surgery, The University of Minnesota Medical School, The Masonic Cancer Center, Minneapolis, MN, 55455, USA

    Denis R. Clohisy

  4. Department of Radiology, The University of Minnesota Medical School, The Masonic Cancer Center, Minneapolis, MN, 55455, USA

    Jerry W. Frolich

Authors
  1. Keith M. Skubitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Carlos Manivel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Denis R. Clohisy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jerry W. Frolich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keith M. Skubitz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Skubitz, K.M., Manivel, J.C., Clohisy, D.R. et al. Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors. Cancer Chemother Pharmacol 64, 635–640 (2009). https://doi.org/10.1007/s00280-009-1010-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-009-1010-0

Keywords

Search

Navigation